智通财经APP获悉，香港联交所最新资料显示，10月24日，微创脑科学(02172)股东将股票由建设亚洲转入国元证券经纪，转仓市值8.56亿港元，占比12.94%。
微创脑科学公布2025年中期业绩，收入约3.83亿元，同比减少6.2%;公司权益股东应占溢利9292.3万元，同比减少35.25%;每股盈利0.16元。截至报告期末，该集团共有8款产品实现出海，累计在34个海外国家或地区实现商业化，涵盖9个神经介入手术量排名全球前十的国家。
智通财经APP获悉，香港联交所最新资料显示，10月24日，微创脑科学(02172)股东将股票由建设亚洲转入国元证券经纪，转仓市值8.56亿港元，占比12.94%。
微创脑科学公布2025年中期业绩，收入约3.83亿元，同比减少6.2%;公司权益股东应占溢利9292.3万元，同比减少35.25%;每股盈利0.16元。截至报告期末，该集团共有8款产品实现出海，累计在34个海外国家或地区实现商业化，涵盖9个神经介入手术量排名全球前十的国家。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.